319 patients

REAL-WORLD STUDY

41 physicians

Belgium 13.5%

France 27.6%

Spain 58.9%

in **3** countries

Prospective • Observational • Single-arm study

NEW PUBLICATION **2022**

An Emollient PLUS Balm Is Useful for the Management of **Xerosis** in Patients Treated for Cancer

XeraCalm A.D

Véronique Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz-Brugués

ASSESSMENTS

At inclusion and after 4 + 2 weeks of use

Practitioners assessed xerosis severity (NCI CTCAE, version 4.0 scale for dry skin) and objective clinical signs: xerosis, erythema, desquamation

Patients assessed subjective clinical signs and the impact of their skin condition on QoL (DLQI)

At the end of the study

Overall effectiveness & tolerance

To evaluate the effectiveness of an emollient PLUS containing an Aquaphilus dolomiae extract (ADE-G1) for the management of xerosis due to anticancer treatment

Adult xerotic cancer patients (any severity) who were prescribed the study product according to usual practice

Participant flow through the study

ENROLMENT — Sept. 2017

Physicians

n=41

Eligible patients

No AEs reported

FOLLOW-UP

Analysed patients

ANALYSES — July 2020

n=319

Whole population

ACCORDING TO ANTICANCER TREATMENT

- **n=111** 34.8% — Chimiotherapy
- **n=19** 6.0% — Hormonotherapy
- **n=106** 33.2% — Targeted therapy
- **n=53** 16.6% — Combined therapy
- **n=30** 9.4% — Radiotherapy

EAU THERMALE Avène

LABORATOIRE DERMATOLOGIQUE

XeraCalm A.D

CANCER-TREATED PATIENTS

Effectiveness on reducing xerosis severity and many others clinical symptoms
Good improvement in **4 weeks** only on Patient Quality of Life

XEROSIS



****Indicates p<0.0001
between baseline and follow-up (Stuart–Maxwell test)

XeraCalm A.D reduced significantly the Xerosis severity grade

62.7%
having a lower grade of xerosis at follow-up

EFFECTIVENESS



****Indicates p<0.0001 between baseline and follow-up
(t test for clinical signs, and Wilcoxon test for DLQI score)

XeraCalm A.D reduced significantly the objective & subjective clinical signs



Overall effectiveness assessed by



"The product was well tolerated, with no clinically significant AEs reported."

EAU THERMALE Avène
LABORATOIRE DERMATOLOGIQUE